SCHEMBL970977

SCHEMBL970977

CN(C)C(=O)c1cnc2sc3c(c2c1)CCN(CC(=O)N1CCN(C2CCC2)CC1)C3

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.38
MAP4K1 Q92918 1/20 0.34
HRH3 Q9Y5N1 8/20 0.34
KDM2B Q8NHM5 1/20 0.33
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CDK4 P11802 2/20 0.32
F10 P00742 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
G6PD P11413 1/20 0.31
HPGD P15428 1/20 0.31
CACNA1B Q00975 1/20 0.31
APBA1 Q02410 1/20 0.31
HSD17B10 Q99714 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969746 0.85 HRH3 (0.41) PARP1HRH3KDM2B
SCHEMBL968565 0.84 PARP1 (0.39) PARP1HRH3HTTNPSR1KDM4E
SCHEMBL967970 0.83 PARP1 (0.40) PARP1HRH3KDM2BHTTNPSR1
SCHEMBL966767 0.82 PARP1 (0.40) PARP1HRH3HTTNPSR1KDM4E
SCHEMBL967455 0.82 PARP1 (0.41) PARP1HRH3KDM4EALDH1A1HPGD
SCHEMBL971597 0.80 PARP1 (0.39) PARP1HRH3HTTNPSR1KDM4E
SCHEMBL970417 0.80 PARP1 (0.40) PARP1HRH3HTTNPSR1KDM4E
SCHEMBL971385 0.80 PARP1 (0.39) PARP1HRH3HTTNPSR1F10
SCHEMBL967692 0.80 PARP1 (0.39) PARP1HRH3HTTKDM4EALDH1A1
SCHEMBL969349 0.79 PARP1 (0.40) PARP1HRH3KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885MAP4K1 3600/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.